Results 61 to 70 of about 9,527 (221)

Long‐term remission in gout: Challenges and future opportunities

Rheumatology &Autoimmunity, EarlyView.
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley   +1 more source

Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study

RMD Open, 2022
Objectives Although uric acid lowering therapies, including xanthine oxidase (XO) inhibition, may reduce the absolute level of blood pressure (BP), the effect of XO inhibition on BP variability is largely unknown.
Yoshio Kobayashi, Atsushi Tanaka, Yuichi Saito, Daigaku Uchida, Koichi Node, Naoto Yokota, Hisako Yoshida, Yuji Koide, Kazuo Matsunaga, Chikara Ueyama   +9 more
doaj   +1 more source

Nitrite supplementation alleviates cerebrovascular dysfunction in chronically stressed mice, but cognitive decline remains

Experimental Physiology, EarlyView.
Abstract This study aimed to determine whether sodium nitrite supplementation prevented chronic stress‐induced cerebrovascular dysfunction and cognitive decline. We hypothesize that nitrite supplementation will prevent the oxidative environment and cerebrovascular dysfunction associated with chronic stress and maintain cognitive health.
Emily Burrage, Tyler Coblentz, Saina S. Prabhu, Nicole M. Eminhizer, Ryan Childers, Randall W. Bryner, Sara E. Lewis, Brooke A. Maxwell, Evan R. DeVallance, Eric E. Kelley, Paul D. Chantler   +10 more
wiley   +1 more source

Guidelines for the treatment of gout: a Swiss perspective. [PDF]

, 2016
Gout is a common condition and its management is suboptimal. A number of guidelines on the management of gout have been published in the last decade by professional societies with the aim of informing the physician of the recommended therapeutic ...
Alromaih, F., So, A., Wüthrich, H.
core   +1 more source

Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants? [PDF]

, 2015
BACKGROUND: Patient recruitment into clinical trials is a major challenge, and the elderly, socially deprived and those with multiple comorbidities are often underrepresented.
BC Martinson, BS Frey, CL Tishler, Claudine G Jennings, E Jones, EJ Emanuel, H Draper, IS Mackenzie, Isla S Mackenzie, J Saunders, JC Wong, Lewis McConnachie, Li Wei, Morris J Brown, N Dickert, PA Rochon, RM Titmuss, S Treweek, SD Halpern, Thomas M MacDonald, TM MacDonald   +20 more
core   +3 more sources

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age

BMC Geriatrics, 2012
Background The incidence of gout rises with increasing age. Management of elderly (≥65 years) gout patients can be challenging due to high rates of comorbidities, such as renal impairment and cardiovascular disease, and concomitant medication use ...
Jackson Robert L, Hunt Barbara, MacDonald Patricia A   +2 more
doaj   +1 more source

Risks Associated with Drug Treatments for Kidney Stones [PDF]

, 2015
Introduction: Renal stones are one of the most painful medical conditions patients experience. For many they are also a recurrent problem. Fortunately, there are a number of drug therapies available to treat symptoms as well as prevent future stone ...
Borofsky, Michael S., Lingeman, James E., York, Nadya   +2 more
core   +1 more source

AIE‐Mediated In Situ Monitoring of Protein Aggregates During Coagulation and Screening of Anticoagulant Agents

Aggregate, Volume 7, Issue 1, January 2026.
The process of screening active monomers via BioSTAS technology. (A) Analyzing the properties and luminescence mechanism of an AIE molecule through density functional theory and MD simulation. (B) The establishment of a screening model, including biosensing and affinity chromatography. (C) Screening and identification of active substances.
Shuxian Zhang, Hui Yuan, Lingling Yang, Xiaoxuan Fan, Keshuai Liu, Rui Mai, Wangyan Zhao, Cheng Liu, Qiang Han, Yongjian Ai, Qionglin Liang, Xueqin Ma, Guoning Chen   +12 more
wiley   +1 more source

An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction

Pharmacology Research & Perspectives
The study objective was to validate febuxostat dosage and administration in pediatric patients with hyperuricemia including gout, using an integrated population pharmacokinetic (PopPK) analysis in the Japanese population.
Ryutaro Iwama, Kimie Nishida, Daisuke Ishii, Takeshi Iijima   +3 more
doaj   +1 more source

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia

The Journal of Clinical Hypertension, 2021
Elevated serum uric acid is a cardiovascular risk factor in patients with hypertension, even when blood pressure (BP) is well controlled. Xanthine oxidoreductase inhibitors (XORi) reduce serum uric acid levels and have several other potential effects ...
Kazuomi Kario, Masafumi Nishizawa, Mari Kiuchi, Arihiro Kiyosue, Fumishi Tomita, Hiroshi Ohtani, Yasuhisa Abe, Hideyo Kuga, Satoshi Miyazaki, Takatoshi Kasai, Makiko Hongou, Takanori Yasu, Jin Kuramochi, Yoshihiro Fukumoto, Satoshi Hoshide, Ichiro Hisatome   +15 more
doaj   +1 more source